We are live on
!
Find out more
ABI
Adamant Biomedical Investments Portfolio holdings
AUM
$418M
This Fund
S&P 500
This Quarter
Est. Return
+5.6%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$401M
AUM Growth
–
Cap. Flow
+$398M
Cap. Flow
% of AUM
99.27%
Top 10 Holdings %
Top 10 Hldgs %
34.69%
Holding
96
New
96
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$19.2M |
| 2 |
CELG
Celgene Corp
CELG
|
+$18.7M |
| 3 |
Biogen
BIIB
|
+$18.1M |
| 4 |
CYTO
Altamira Therapeutics Ltd
CYTO
|
+$13.4M |
| 5 |
Amgen
AMGN
|
+$13.1M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 86.61% |
| 2 | Financials | 1.21% |
| 3 | Industrials | 0.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Bristol-Myers Squibb
BMY
$132B
| $2.56M | 0.64% |
+50,000
| New | +$2.5M |
|
52
Zimmer Biomet
ZBH
$18.4B
| $2.51M | 0.63% |
+25,750
| New | +$2.53M |
|
|
RVNC
53
DELISTED
Revance Therapeutics, Inc.
RVNC
| $2.51M | 0.63% |
+130,000
| New | +$3.39M |
|
|
CERN
54
DELISTED
Cerner Corp
CERN
| $2.38M | 0.59% |
+40,000
| New | +$2.25M |
|
55
Merck
MRK
$318B
| $2.37M | 0.59% |
+41,920
| New | +$2.35M |
|
|
AKRX
56
DELISTED
Akorn Inc
AKRX
| $2.18M | 0.54% |
+60,000
| New | +$2.15M |
|
|
MDVN
57
DELISTED
MEDIVATION, INC.
MDVN
| $1.98M | 0.49% |
+40,000
| New | +$1.7M |
|
58
United Therapeutics
UTHR
$23.1B
| $1.93M | 0.48% |
+15,000
| New | +$1.55M |
|
59
Alkermes
ALKS
$8.25B
| $1.93M | 0.48% |
+45,000
| New | +$2.02M |
|
60
DaVita
DVA
$11.7B
| $1.9M | 0.47% |
+26,000
| New | +$1.9M |
|
61
Direxion Daily Small Cap Bull 3x ETF
TNA
$1.47B
| $1.9M | 0.47% |
+60,000
| New | +$2.19M |
|
62
Intuitive Surgical
ISRG
$134B
| $1.85M | 0.46% |
+36,000
| New | +$1.79M |
|
63
Alnylam Pharmaceuticals
ALNY
$29.3B
| $1.8M | 0.45% |
+23,000
| New | +$1.48M |
|
64
Pfizer
PFE
$153B
| $1.77M | 0.44% |
+63,240
| New | +$1.77M |
|
65
MannKind Corp
MNKD
$1.32B
| $1.77M | 0.44% |
+60,000
| New | +$2.37M |
|
66
Innoviva
INVA
$1.48B
| $1.71M | 0.43% |
+100,000
| New | +$2.3M |
|
|
ARIA
67
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $1.62M | 0.4% |
+300,000
| New | +$1.75M |
|
|
VAR
68
DELISTED
Varian Medical Systems, Inc.
VAR
| $1.6M | 0.4% |
+22,808
| New | +$1.68M |
|
|
CBST
69
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
| $1.59M | 0.4% |
+24,000
| New | +$1.58M |
|
|
SGEN
70
DELISTED
Seagen Inc. Common Stock
SGEN
| $1.49M | 0.37% |
+40,000
| New | +$1.57M |
|
71
Edwards Lifesciences
EW
$51.7B
| $1.48M | 0.37% |
+87,000
| New | +$1.37M |
|
|
BCR
72
DELISTED
CR Bard Inc.
BCR
| $1.43M | 0.36% |
+10,000
| New | +$1.48M |
|
|
ATHN
73
DELISTED
Athenahealth, Inc.
ATHN
| $1.32M | 0.33% |
+10,000
| New | +$1.32M |
|
|
WMGI
74
DELISTED
Wright Medical Group Inc
WMGI
| $1.15M | 0.29% |
+38,000
| New | +$1.17M |
|
|
OCR
75
DELISTED
OMNICARE INC
OCR
| $1.12M | 0.28% |
+18,000
| New | +$1.14M |
|
Similar funds
AGCJ
ACM
RNS
NTP
MMC
LOM
CAMI
NES
Adamant Biomedical Investments's Q3 2014 Portfolio in Review
Q3 2014 is the first quarter with a 13F filing on record for Adamant Biomedical Investments, which disclosed 96 positions worth $401M. Its ten largest holdings account for 35% of the portfolio.
Its largest position is Gilead Sciences: 196,390 shares worth $20.9M.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, followed by Financials and Industrials.
- Adamant Biomedical Investments's largest Q3 2014 buy was Gilead Sciences: 196,390 shares worth $20.9M.
- Adamant Biomedical Investments's ten largest holdings make up 35% of its $401M portfolio in Q3 2014.
- Adamant Biomedical Investments disclosed 96 positions in Q3 2014, its first 13F filing on record.
Based on Adamant Biomedical Investments's 13F filing for Q3 2014, filed 14 Nov 2014.